Andrew Pasternak
Direttore/Membro del Consiglio presso FORWARD WATER TECHNOLOGIES CORP.
Profilo
Andrew Pasternak is currently the Executive Director at GreenCentre Canada, Director at Forward Water Technologies, Inc., and Independent Director at Forward Water Technologies Corp.
He previously held positions as Director of Research & Commercialization at Transition Therapeutics, Covalon Technologies Ltd., Protana, Inc., and MDS Sciex.
Dr. Pasternak holds a doctorate from Northwestern University and an MBA from the University of Toronto.
Posizioni attive di Andrew Pasternak
Società | Posizione | Inizio |
---|---|---|
FORWARD WATER TECHNOLOGIES CORP. | Direttore/Membro del Consiglio | 20/10/2021 |
Forward Water Technologies, Inc.
Forward Water Technologies, Inc. Environmental ServicesIndustrial Services Forward Water Technologies, Inc. is a Canadian company that specializes in the commercialization of its proprietary forward osmosis technology. The company was founded in 2012 by Greencentre and is based on a platform technology developed at Queen's University in Kingston. The company's focus is on large-scale implementation of its technology in industrial wastewater, oil and gas, mining, agriculture, and municipal water supply and re-use market sectors. The company is based in Mississauga, Canada. The technology allows for the reduction of challenging waste streams with high levels of dissolved salts while simultaneously returning fresh water for re-use or surface release. C. Howie Honeyman has been the CEO of the company since 2015. | Direttore/Membro del Consiglio | 01/01/2020 |
GreenCentre Canada
GreenCentre Canada Chemicals: SpecialtyProcess Industries GreenCentre Canada manufactures chemical products. It offers technologies that have been in-licensed, iron catalysts for fine polymers and chemical compounds catalytic hydrogenation of esters and dehydrogenative coupling of alcohols eco-friendly biocide for coatings switchable water high performance catalysts for biodegradable polyesters metal-free hydrogenation catalysts carboxylic acid amidation 'gemini' multi-purpose surfactants precursors for atomic layer deposition. The company was founded in 2009 and is headquartered in Kingston, the United Kingdom. | Direttore/Membro del Consiglio | 01/08/2021 |
Precedenti posizioni note di Andrew Pasternak
Società | Posizione | Fine |
---|---|---|
TRANSITION THERAPEUTICS INC | Corporate Officer/Principal | - |
COVALON TECHNOLOGIES LTD. | Corporate Officer/Principal | - |
Protana, Inc.
Protana, Inc. Miscellaneous Commercial ServicesCommercial Services Protana, Inc. provides pharmaceutical and biotechnology research services. It provides protein identification, protein interaction mapping, differential analysis, biomarker discovery, chemical proteomics, and insilico drug design services. The company provides services to medical and biopharmaceutical companies. The company headquartered in Toronto, Canada. | Corporate Officer/Principal | - |
MDS Sciex
MDS Sciex Medical SpecialtiesHealth Technology MDS Sciex manufactures and supplies industrial equipment. The company is headquartered in Concord, Canada. | Corporate Officer/Principal | - |
Formazione di Andrew Pasternak
Northwestern University | Doctorate Degree |
University of Toronto | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
FORWARD WATER TECHNOLOGIES CORP. | Finance |
COVALON TECHNOLOGIES LTD. | Health Technology |
Aziende private | 5 |
---|---|
Forward Water Technologies, Inc.
Forward Water Technologies, Inc. Environmental ServicesIndustrial Services Forward Water Technologies, Inc. is a Canadian company that specializes in the commercialization of its proprietary forward osmosis technology. The company was founded in 2012 by Greencentre and is based on a platform technology developed at Queen's University in Kingston. The company's focus is on large-scale implementation of its technology in industrial wastewater, oil and gas, mining, agriculture, and municipal water supply and re-use market sectors. The company is based in Mississauga, Canada. The technology allows for the reduction of challenging waste streams with high levels of dissolved salts while simultaneously returning fresh water for re-use or surface release. C. Howie Honeyman has been the CEO of the company since 2015. | Industrial Services |
GreenCentre Canada
GreenCentre Canada Chemicals: SpecialtyProcess Industries GreenCentre Canada manufactures chemical products. It offers technologies that have been in-licensed, iron catalysts for fine polymers and chemical compounds catalytic hydrogenation of esters and dehydrogenative coupling of alcohols eco-friendly biocide for coatings switchable water high performance catalysts for biodegradable polyesters metal-free hydrogenation catalysts carboxylic acid amidation 'gemini' multi-purpose surfactants precursors for atomic layer deposition. The company was founded in 2009 and is headquartered in Kingston, the United Kingdom. | Process Industries |
MDS Sciex
MDS Sciex Medical SpecialtiesHealth Technology MDS Sciex manufactures and supplies industrial equipment. The company is headquartered in Concord, Canada. | Health Technology |
Protana, Inc.
Protana, Inc. Miscellaneous Commercial ServicesCommercial Services Protana, Inc. provides pharmaceutical and biotechnology research services. It provides protein identification, protein interaction mapping, differential analysis, biomarker discovery, chemical proteomics, and insilico drug design services. The company provides services to medical and biopharmaceutical companies. The company headquartered in Toronto, Canada. | Commercial Services |
Transition Therapeutics, Inc.
Transition Therapeutics, Inc. Medical SpecialtiesHealth Technology Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada. | Health Technology |
- Borsa valori
- Insiders
- Andrew Pasternak